Florian Heitz
Papers
2
Total Citations
54
H-Index
2
About
Florian Heitz is a leading gynecologic oncologist whose research focuses on precision medicine in ovarian cancer, particularly through the lens of homologous recombination deficiency (HRD). His most impactful work, a 2022 study with 40 citations, provides a landmark evaluation of HRD as a biomarker in a real-world cohort of 514 ovarian carcinoma samples. By employing next-generation sequencing to analyze BRCA1/BRCA2 mutations alongside over 26,000 single-nucleotide polymorphisms, Heitz demonstrated how HRD testing can define targeted therapy strategies, directly influencing clinical decision-making for patients. This contribution has been pivotal in translating complex genomic data into actionable treatment pathways, positioning HRD status as a cornerstone of personalized ovarian cancer care. Beyond biomarker research, Heitz has advanced surgical oncology by investigating the implementation of robot-assisted gynecologic surgery across diverse patient populations, including those with low and high body mass index (BMI), as detailed in his 2014 work. His dual focus on molecular diagnostics and minimally invasive techniques underscores a commitment to improving both the biological understanding and surgical outcomes of gynecologic cancers, making him a key figure in the evolution of modern gynecologic oncology.
Research Focus
Key Achievements
Top Papers
- 1
- 2